"Danaher ( NYSE: DHR) is acquiring Masimo ( NASDAQ: MASI) for $9.9 billion in an all-cash deal that values the medical technology company at $180 per share. The transaction, announced February 17, 2026, represents a nearly 40% premium over Masimo's closing price on Friday, February 13, 2026. Masimo specializes in pulse oximetry and patient monitoring technology, generating $2.18 billion in revenue over the trailing 12 months."
"The company reported $371.5 million in revenue for Q3 2025, with non-GAAP EPS of $1.32, up 38% year-over-year. Masimo recently streamlined operations by selling its Sound United consumer audio division, allowing management to refocus on core medical device business. This acquisition follows Danaher's playbook of adding high-quality diagnostics and life sciences assets. With $24.57 billion in trailing revenue and $7.14 billion in EBITDA, Danaher has the financial capacity to absorb this deal, which represents approximately 6.8% of its $145.88 billion market cap."
Danaher is buying Masimo for $9.9 billion in an all-cash transaction valuing Masimo at $180 per share, a nearly 40% premium to the February 13, 2026 closing price. Masimo generated $2.18 billion in trailing twelve-month revenue and reported $371.5 million in Q3 2025 revenue with non-GAAP EPS of $1.32, up 38% year-over-year. Masimo sold its Sound United consumer audio division to focus on core medical devices. Danaher had $24.57 billion in trailing revenue and $7.14 billion in EBITDA, and expects the deal to be earnings-accretive with significant synergies. The transaction requires shareholder and regulatory approval and is expected to close in H2 2026.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]